New Polio Vaccine Technology Promises Affordability and Safety

Researchers at the University of Leeds have made significant progress toward developing a more affordable and safer polio vaccine using virus-like particles (VLPs). These particles, which mimic the outer protein shell of poliovirus but are empty inside, trigger an immune response without the risk of infection.

The study, published in Nature Communications, tested various cell types as expression systems for generating VLPs. Results show that VLPs produced in yeast and insect cells can perform equally or better than the current inactivated polio vaccine (IPV). 

According to Professor Nicola Stonehouse, a senior author on the paper, “Any vaccine is only as effective as the number of children that it reaches.  The key is to make vaccines universally accessible, as all children have a right to be protected from diseases such as polio, no matter where they live. Ultimately, VLPs would significantly contribute to vaccine equity."

The new VLP-based vaccine offers several advantages over current options. Unlike IPV, which requires high levels of bio-containment due to the risk of live poliovirus leaks, VLPs are non-infectious and can be handled under less stringent conditions. They are also more temperature stable and less expensive to produce, potentially improving equitable access to vaccination.

As the world moves toward polio eradication, VLP-based vaccines could play a crucial role in maintaining protection without the risks associated with current oral polio vaccines. The next generation of polio vaccinations are likely to be produced in yeast or insect cells, which have shown effectiveness in animal studies and are favored by companies for their low cost.

This research builds on the success of VLP technology already used in vaccines for hepatitis B and human papillomavirus, bringing hope for a safer, more accessible solution in the global fight against polio.